Literature DB >> 2965205

Dopamine stimulates release of thyrotrophin-releasing hormone from perfused intact rat hypothalamus via hypothalamic D2-receptors.

B M Lewis1, C Dieguez, M D Lewis, M F Scanlon.   

Abstract

We have studied the effect of dopamine together with agonist and antagonist drugs of different specificities on the release of TRH from the perfused, intact hypothalamus of the adult rat in vitro. Dopamine produced a dose-related stimulatory effect on TRH release with maximal effect being achieved at 1 mumol/l (increase over basal, 118 +/- 16.5 (S.E.M.) fmol TRH; P less than 0.001 vs basal). This effect was mimicked by the specific D2-agonist drugs bromocriptine (0.1 mumol/l) and LY 171555 (0.1 mumol/l) (increase over basal values, 137.5 +/- 13.75 fmol and 158.6 +/- 10.7 fmol respectively; P less than 0.001 vs basal), but not by the D1-agonist SKF 38393A. The stimulatory effect of dopamine (1 mumol/l) was blocked in a stereospecific manner by the active (D) but not by the inactive (L) isomers of the dopamine antagonist butaclamol. Similar blockade was achieved with the specific D2-antagonist domperidone (0.01 mumol/l) whereas the D1-antagonist SCH 23390 was only effective when used at a concentration 100 times greater. Lower concentrations (0.01 mumol/l) of this D1-antagonist did not block the stimulatory effect of dopamine. High-performance liquid chromatography characterization of the material secreted within the hypothalamus showed one single peak of immunoreactive material which coeluted with synthetic TRH. These data suggest that dopamine exerts a stimulatory role in the control of hypothalamic TRH release by acting at specific D2-receptors.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2965205     DOI: 10.1677/joe.0.1150419

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  8 in total

1.  Dopamine-Responsive Growth-Hormone Deficiency and Central Hypothyroidism in Sepiapterin Reductase Deficiency.

Authors:  Matthias Zielonka; Nawal Makhseed; Nenad Blau; Markus Bettendorf; Georg Friedrich Hoffmann; Thomas Opladen
Journal:  JIMD Rep       Date:  2015-05-26

2.  TSH and PRL, side-effect markers in aripiprazole treatment: adjunctive aripiprazole-induced thyrotropin oversuppression in a young man with schizophrenia.

Authors:  Hidenobu Ohta; Satoru Inoue; Koichiro Hara; Akihiko Watanabe
Journal:  BMJ Case Rep       Date:  2017-08-22

Review 3.  Drugs that suppress TSH or cause central hypothyroidism.

Authors:  Bryan R Haugen
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

4.  Comparative distribution of somatostatin and somatostatin receptors in PTU-induced hypothyroidism.

Authors:  Sneha Singh; Rishi K Somvanshi; Vandana Panda; Ujendra Kumar
Journal:  Endocrine       Date:  2020-04-25       Impact factor: 3.633

5.  Thyroid diseases in patients with acromegaly.

Authors:  Anna Maria Dąbrowska; Jerzy Stanisław Tarach; Maria Kurowska; Andrzej Nowakowski
Journal:  Arch Med Sci       Date:  2013-08-12       Impact factor: 3.318

Review 6.  An Overview on Different L-Thyroxine (l-T4) Formulations and Factors Potentially Influencing the Treatment of Congenital Hypothyroidism During the First 3 Years of Life.

Authors:  Stefano Stagi; Giovanna Municchi; Marta Ferrari; Malgorzata Gabriela Wasniewska
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

Review 7.  Physiological and Pathological Role of Circadian Hormones in Osteoarthritis: Dose-Dependent or Time-Dependent?

Authors:  Farhad Md Hossain; Yunkyung Hong; Yunho Jin; Jeonghyun Choi; Yonggeun Hong
Journal:  J Clin Med       Date:  2019-09-08       Impact factor: 4.241

8.  Graves' Disease after Adrenalectomy for Cushing's Syndrome.

Authors:  Yuji Hiromatsu; Hiroyuki Eguchi; Yui Nakamura; Kei Mukohara
Journal:  Intern Med       Date:  2020-09-05       Impact factor: 1.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.